Merck to buy VC-backed OncoImmune for $425m

Merck has agreed to acquire OncoImmune, a clinical-stage biopharmaceutical company, for $425 million in cash.

23 November 2020•5 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Healthcare M&A Deals Briefs